Login

Claudia D’Orsi

ORCID: 0000-0002-0466-9110
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5028623966
Research Areas
  • Hematological disorders and diagnostics
  • Inflammasome and immune disorders
  • Thermal Regulation in Medicine
  • Orthopedic Infections and Treatments
  • Cystic Fibrosis Research Advances
  • Nematode management and characterization studies

University of Genoa
 2022-2023

 Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method
OPENALEX - Publications 
Federica Pigliasco Alessia Cafaro Manuela Stella Giammarco Baiardi Sebastiano Barco and 8 more Nicoletta Pedemonte Claudia D’Orsi Federico Cresta Rosaria Casciaro Carlo Castellani Maria Grazia Calevo Francesca Mattioli Giuliana Cangemi

The new breakthrough cystic fibrosis (CF) drug combination of ivacaftor (IVA), tezacaftor (TEZ), and elexacaftor (ELX), namely “caftor” drugs, directly modulates the activity trafficking defective CF transmembrane conductance regulator protein (CFTR) underlying disease. role therapeutic monitoring (TDM) caftor drugs in clinical settings has recently been established. availability reliable robust analytical methods for quantification IVA, TEZ, ELX is essential to support...

10.3390/biomedicines11020628 article EN cc-by Biomedicines 2023-02-20
 Clinical characterization, long-term follow-up, and response to treatment of patients with syndrome of undifferentiated recurrent fever (SURF)
OPENALEX - Publications 
Diana Sutera Marta Bustaffa Riccardo Papa Caterina Matucci‐Cerinic Simona Matarese and 8 more Claudia D’Orsi Federica Penco Ignazia Prigione Serena Palmeri Francesca Bovis Stefano Volpi Roberta Caorsi Marco Gattorno

10.1016/j.semarthrit.2022.152024 article EN Seminars in Arthritis and Rheumatism 2022-05-10
Coming Soon ...